drugset / Trial / NCT06883526
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
RandomizedSequentialOpen-labelTreatment
Summary
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Timeline
- Start
- 2025-05-16
- Primary completion
- 2027-04
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gecacitinib | Unknown | — | Oral |
| Subject | ZG005 | Unknown | 20 mg/kg | Intravenous |